Medicines Co. Hits New 52-Week High at $40.32 (MDCO)
Shares of Medicines (NASDAQ:MDCO) hit a new 52-week high during mid-day trading on Friday, AnalystRatings.Net reports. The stock traded as high as $40.32 and last traded at $39.99, with a volume of 1,431,363 shares trading hands. The stock had previously closed at $38.36.
Several analysts have recently commented on the stock. Analysts at RBC Capital raised their price target on shares of Medicines from $41.00 to $50.00 in a research note to investors on Thursday, December 5th. They now have an “outperform” rating on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Medicines in a research note to investors on Thursday, November 28th. They now have a $38.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $40.31.
In other Medicines news, CEO Clive Meanwell sold 27,929 shares of the stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $38.13, for a total value of $1,064,932.77. Following the completion of the transaction, the chief executive officer now directly owns 297,773 shares in the company, valued at approximately $11,354,084. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Medicines (NASDAQ:MDCO) last released its earnings data on Wednesday, October 23rd. The company reported $0.47 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.24 by $0.23. The company had revenue of $173.45 million for the quarter, compared to the consensus estimate of $173.86 million. During the same quarter in the previous year, the company posted $0.40 earnings per share. The company’s revenue for the quarter was up 27.4% on a year-over-year basis.
The Medicines Company is a pharmaceutical company focused on the treatment of critical care patients through the delivery of medicines to the global hospital marketplace.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.